目的 探討平消膠囊聯(lián)合注射用卡瑞利珠單抗治療非小細(xì)胞肺癌的臨床療效。方法 選取空軍第九八六醫(yī)院在2021年3月—2024年2月收治的100例非小細(xì)胞肺癌患者，按隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，各包括50例。對(duì)照組患者靜脈滴注注射用卡瑞利珠單抗，200 mg/次，每3周1次。治療組患者于對(duì)照組基礎(chǔ)上口服平消膠囊，4粒/次，3次/d。3周為1個(gè)周期，兩組持續(xù)治療4個(gè)周期。比較兩組臨床療效、健康狀態(tài)、生活質(zhì)量、淋巴細(xì)胞和血清指標(biāo)。結(jié)果 治療組、對(duì)照組的疾病控制率分別為92.00%、76.00%，組間比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，兩組KPS評(píng)分高于治療前（P＜0.05），與對(duì)照組相比，治療組的KPS評(píng)分更高（P＜0.05）。治療后，兩組功能評(píng)分、總健康評(píng)分、癥狀評(píng)分均低于治療前（P＜0.05）；治療組的QLQ-C30各項(xiàng)評(píng)分低于對(duì)照組（P＜0.05）。治療后，兩組的CD4⁺、CD4⁺/CD8⁺高于治療前（P＜0.05）；治療組的CD4⁺、CD4⁺/CD8⁺高于對(duì)照組（P＜0.05）。治療后，兩組的血清神經(jīng)元特異性烯醇化酶（NSE）、細(xì)胞角蛋白19片段抗原（CYFRA21-1）、腫瘤特異性生長(zhǎng)因子（TSGF）水平均顯著降低（P＜0.05），且治療組血清腫瘤標(biāo)志物水平較對(duì)照組更低（P＜0.05）。結(jié)論 平消膠囊聯(lián)合注射用卡瑞利珠單抗治療非小細(xì)胞肺癌可改善患者健康狀態(tài)和生活質(zhì)量，提高免疫功能，降低腫瘤標(biāo)志物水平。

Objective To investigate the clinical effect of Pingxiao Capsules combined with Carrilizumab for injection in treatment of non-small cell lung cancer. Methods A total of 100 patients with non-small cell lung cancer admitted to the 986th Air Force Hospital from March 2021 to February 2024 were selected and divided into control group and treatment group according to random number table method, with 50 cases in each group. Patients in the control group were iv Carrilizumab for injection, 200 mg/time, once every 3 weeks. Patients in the treatment group were po Pingxiao Capsules on the basis of the control group, 4 capsules/time, 3 times daily. Three weeks was one course, and patients in both groups were treated continuously for four courses. The clinical efficacy, health status, quality of life, lymphocyte, and serum indexes were compared between two groups. Results The disease control rate of treatment group and control group was 92.00% and 76.00%, respectively, and the difference was statistically significant between groups (P < 0.05). After treatment, KPS scores in both groups were higher than theses before treatment (P < 0.05), and KPS scores in the treatment group were higher than those in the control group (P < 0.05). After treatment, the functional scores, total health scores, and symptom scores of both groups were lower than theses before treatment (P < 0.05). The scores of QLQ-C30 in the treatment group were lower than those in the control group (P < 0.05). After treatment, CD4⁺ and CD4⁺/CD8⁺ in both groups were higher than these before treatment (P < 0.05). CD4⁺ and CD4⁺/CD8⁺ in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of NSE, CYFRA21-1, and TSGF in both groups were significantly decreased (P < 0.05), and the serum tumor marker levels in the treatment group were lower than those in the control group (P < 0.05). Conclusion Pingxiao Capsules combined with Carrilizumab for injection can improve the health status and quality of life of patients with non-small cell lung cancer, improve immune function and reduce the level of tumor markers.

R979.1

空軍軍醫(yī)大學(xué)臨床研究項(xiàng)目（2023 LC2331）